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Abstract
Purpose: Previous positron emission tomography (PET) studies have shown increased 2-
deoxy-2-[18F]fluoro-D-glucose (FDG) uptake in joints of patients with osteoarthritis (OA) and
inflamed joints of patients with rheumatoid arthritis (RA). This study compares FDG uptake in
joints of RA and OA patients and FDG-uptake with clinical signs of inflammation.
Procedures: FDG-PET scans of hands and wrists were performed in patients with RA and
primary OA. PET data were compared with clinical data.
Results: 29% of RA joints and 6% of OA joints showed elevated FDG-uptake. The level of
uptake in PET-positive OA joints was not significantly different from that in RA joints. The
majority of PET results of RA joints corresponded with clinical findings. Clinical synovitis was
found some OA joints with FDG-uptake.
Conclusions: FDG-uptake was observed in the majority of clinically inflamed RA joints and in a
few OA joints with no significant difference in uptake level. The latter may be due to secondary
synovitis.
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Introduction
In clinical practice, 2-deoxy-2-[F-18]fluoro-D-glucose(FDG) uptake is often observed in large joints on whole
body images, most likely due to degenerative changes and
aging [1Y3]. In fact, diffuse FDG shoulder uptake on
positron emission tomography (PET) was associated with
clinical findings of osteoarthritis (OA) [1], and FDG uptake
in the vertebral column was caused by degenerative changes
in facet joints [2]. FDG joint uptake may also reflect
arthritis because FDG uptake has also been noticed in
inflamed joints of autoimmune diseases, among which is
rheumatoid arthritis (RA) [4Y6]. RA is a chronic inflamma-
tory disease in which small hand and feet joints are
predominantly affected, but large joints may also be
involved. Due to technical limitations, among which is
attenuation, FDG uptake in small hand joints is usually not
seen on whole-body images. To date, a direct comparison
between FDG uptake in inflamed joints of patients with RA
and degenerative joints of patients with OA has not been made.
It is unclear whether the level of FDG uptake in inflamed joints
of RA patients differs from that of degenerative joints.
The aims of the present study were (1) to compare FDG
uptake in hand and wrist joints of patients with RA and OA
and (2) to assess whether there is a relation between FDG
uptake and clinical findings.Correspondence to: E. H. Elzinga; e-mail: eh.elzinga@vumc.nl
Materials and Methods
Patients
A total of 25 patients were included, of which 14 (10 women, 4
men) had been diagnosed with RA, 6 (all women) with primary
OA, and 5 (all women) with fibromyalgia (FM). FM patients were
included as a control group because FM is a syndrome with no
known anatomical abnormalities and/or inflammatory symptoms.
The mean ages of RA, OA, and FM patients were 57T7, 55T11,
and 32T11 years, respectively. RA patients fulfilled American
College of Rheumatology criteria [7] for their diagnosis and had
active RA with a mean disease activity score (DAS28) of 5.2T0.7.
The mean disease duration of RA patients was 9T6 years (range
1Y22 years). All included RA patients were on treatment with one
or two disease-modifying drugs (methotrexate n=12, sulfasalazine
n=2, hydroxychoroquine n=1, and leflunomide n=1). In addition,
seven RA patients were treated with nonsteroidal anti-inflammatory
drugs and three patients were treated with prednisone with at a
maximum dose of 10 mg daily. This study focuses on inflammation
in hand and wrist joints because of the predominant localization of
RA in small joints. Only patients with arthritis of at least two hand
or wrist joints were included. At inclusion, a rheumatologist
determined disease activity in hand joints and wrists. Large joints
were not included in this study. In RA patients, all metacarpopha-
langeal (MCP), proximal interphalangeal (PIP), and wrist joints
were evaluated (total number of 22 joints per patient). At the time of
scanning, at least two clinically swollen joints of hands and/or wrists
were present. In addition to evaluation of MCP, PIP, and wrist
joints, in OA patients, the carpometacarpal 1 (CMC1) and all distal
interphalangeal (DIP) joints were also evaluated, as these joints are
frequently affected in primary OA but not in RA (total of 32 joints
per OA patient). All OA patients had at least one clinically affected
joint at inclusion. In both RA and OA patients, all hand and wrist
joints were scored for clinical synovial swelling. Hand and wrist
joints of FM patients lacked clinical signs of OA and synovial
swelling, which was determined by clinical examination of MCP,
PIP, DIP, CMC1, and wrist joints. The study protocol was approved
by the medical ethics committee of the VU University Medical
Centre. All patients gave written informed consent prior to scanning.
PET Imaging Acquisitions
PET scans were performed using a ECAT EXACT HR+ scanner
(CTI/Siemens, Knoxville, TN, USA). This whole-body scanner
enables the acquisition of 63 contiguous transaxial slices, covering
an axial field of view of 15.5 cm. Prior to scanning, patients fasted
for at least 6 h. Plasma glucose levels, measured just prior to
intravenous administration of FDG, were all within normal limits.
Patients with a bodyweight of less than 85 kg were injected with
370 MBq [18F]FDG, otherwise injected dose was increased to 555
MBq. After a resting period of 60 min, to allow for uptake of FDG,
patients were transferred to the scanning room. Whole-body
images were not suitable for investigation of the hand and wrist
joints because FDG uptake in small hand joints is not seen on
whole-body images with the arms of the patients positioned
adjacent to the body. The latter is caused by attenuation in and
scattered radiation from the pelvic region, the proximity of the
bladder, and the limited spatial resolution at the edge of the
transaxial field of view. Therefore, a static emission scan of 5 min
of hands and wrists was acquired, following positioning of hands
and wrists in the center of the field of view of the scanner. 2-D
data acquisition was used. PET scans were corrected for decay,
scatter, attenuation, randoms, and dead time. Images were
reconstructed as 128128 matrices using filtered back projection
with a Hanning filter (cut-off 0.5 cycles/pixel), resulting in a
transaxial spatial resolution of õ7 mm full width at half
maximum.
Image Analysis
Coronal, sagital, and transverse images were used for analysis. All
hand and wrists joints, as mentioned above, were investigated. First,
uptake in joints was scored as positive in case of focally increased
uptake of FDG. Next, regions of interest (ROIs) were drawn on
PET-positive areas in these joints. Control regions were drawn on
metacarpal bone outside these joints. Joint-to-control (J/C) ratios
were calculated, giving semiquantitative data. In joints without
focally increased FDG uptake, no further analysis was performed.
Control ROIs were drawn upon MCP joints of FM patients to allow
comparison of J/C ratios with RA and OA. Finally, PET data were
compared with clinical data.
Statistical Analysis
Differences of the mean J/C ratios between RA, OA, and FM
joints were compared using multilevel analysis because the
observations of joints within one patient are highly correlated.
Multilevel analysis [8] is a regression technique that takes into
account possible dependency of observations. In this situation, two
levels are considered: joints within patients. An independent-
samples t test was used to compare the number of PET-positive
joints between RA, OA, and FM.
Results
Clinical Data
Of the 22 hand and wrists joints evaluated, the mean
number of clinically swollen joints per RA patient was
seven (range 2Y17). In OA patients, the number of joints
(out of 32 evaluated joints) with (secondary) synovial
Table 1. Comparison of the percentage of joints with and without FDG uptake in RA, OA and FM patients, together with the level of uptake in positive
joints, expressed as J/C ratios
Group Total number of
investigated joints
Total number of joints with
clinical synovial swelling
PET positive joints PET negative joints J/C ratio of joint uptake on
PET (mean T SD)
RA 308 94 (31%) 88 (29%) 220 (71%) 5.4 (T1.2)
OA 192 3 (2%) 12 (6%) 128 (97%) 3.7 (T1.7)
FM 110 0 0 (0%) 110 (100%) 1.7 (T0.5)
In addition, the number of joints with clinical synovial swelling is included
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swelling ranged from 0 to 2. No signs of synovial swelling
were observed in joints of FM patients. The total number of
joints with clinical swelling in the RA, OA, and FM groups
is listed in Table 1.
FDG Images
In Fig. 1, FDG uptake images are shown of hands and wrists
of representative patients from each patient group. The
number of PET-positive joints in RA patients was signifi-
cantly higher than in OA patients (pG0.001) (Table 1). No
FDG uptake was found in joints of FM patients. FDG uptake
was noticed in only 12 out of 192 OA joints investigated. The
level of FDG uptake in these joints did not differ significantly
from that in RA joints. FDG uptake in joints of RA and OA
patients was significantly higher than that in FM patients
(p=0.01 and p=0.03, respectively). Background activity in
synovial tissue was slightly higher than in metacarpal bone,
hence the elevated J/C ratio in FM patients (Table 1).
Relation between FDG Images and Clinical Data
RA Patients In 76% of the joints, there was correspon-
dence between clinical findings and PET results, i.e., the
majority of joints with synovial swelling showed increased
FDG uptake and, vice versa, most joints without clinical
signs of inflammation showed normal FDG uptake. Never-
theless, discrepancies between FDG images and clinical
examinations were noticed. In 13% (41 out of 308) of RA
joints, there were signs of clinical synovitis, whereas no
focally increased FDG uptake was seen. In addition, 11%
(35 out of 308) of RA joints evaluated did not show any
clinical signs of inflammation while locally enhanced FDG
uptake was observed.
OA and FM Patients Twelve of the joints evaluated in OA
patients (6%) showed increased FDG uptake. Three of these
joints showed synovial swelling (secondary to OA) at
clinical evaluation. No FDG uptake was observed in any
of the joints of FM patients, in agreement with the absence
of synovial swelling in all these joints.
Discussion
In the present study, most RA joints with clinical signs of
inflammation showed increased FDG uptake. The number
of PET-positive joints in RA patients was significantly
higher than that in OA patients. The level of FDG uptake
was, however, similar in PET-positive RA and OA joints.
The control joints of FM patients, without clinical signs of
inflammation and degenerative changes, did not show any
uptake.
A small number of OA joints showed FDG uptake.
Unfortunately, x-rays of the hands of these OA patients
were not available. Therefore, it was not possible to
correlate FDG uptake with signs of OA. FDG uptake in
OA joints could be due to several factors. First, increased
FDG uptake may reflect enhanced metabolic activity in
bone/cartilage due to an inflammatory process involved
in the mechanism of cartilage destruction [9]. Alterna-
tively, secondary synovitis in osteoarthritic joints may also
result in increased FDG uptake in OA joints, as has been
studied by ultrasound [10]. This second possibility is
supported by the present observation that three out of 12
OA joints with FDG uptake showed synovial swelling at
clinical examination.
Although patients had active disease at inclusion, the
actual number of PET-positive joints in RA patients was
relatively low (29%). This can be explained by the fact that
Fig. 1. PET images of A an RA patient with FDG uptake in
MCP joints and both wrists (arrows); B an OA patient with
FDG uptake in CMC1, the base of the second metacarpal
joint, and PIP 5 (arrows); and C an FM patient without FDG
uptake
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only 31% of the investigated hand joints of RA patients
showed synovial swelling at the time of scanning. The FDG
PET results corresponded in the majority (76%) of
evaluated joints with clinical assessment of synovial
swelling. This finding corresponded to observations in RA
patients by Beckers et al. [5], who compared FDG PET with
ultrasound and clinical examination of joints. In addition,
Goerres et al. [11], showed matched clinical and FDG-PET
results in 78% of joints of RA patients responding to
infliximab therapy.
Although these two former studies have also compared
FDG-PET to clinical findings in RA patients, no compar-
ison has been made between FDG-PET in RA patients and
OA patients, which was the focus of our study. In addition,
previous FDG studies in RA patients did not include a
control group without inflammatory joint disease.
Despite matching of PET and clinical data in most of the
joints investigated, absence of a PET signal was found in
13% of RA joints with clinical synovial swelling. Clinically
inflamed joints may lack increased FDG uptake as a result
of severe deformations of the joints, which may also have
hampered the judgement of the presence of clinical
synovitis. The latter explanation is strengthened by the fact
that the observed mismatch between clinical signs of
inflammation and lack of increased FDG uptake could be
reduced by a factor of two if patients with severe joint
deformation were excluded from the analysis. It should be
noted that clinical judgement of synovitis can also be dif-
ficult in case of fibrotic synovial tissue, which may mimic
synovitis [12]. Furthermore, additional mismatching of FDG
PET and clinical data was found in 11% of the evaluated
joints, in which FDG uptake was observed in the absence of
clinical signs of inflammation. A positive signal on FDG-
PET in clinically noninflamed joints may indicate visualiza-
tion of subclinical synovitis. Subclinical synovitis has been
found in histological studies of synovial tissue by Kraan et al.
[13]. Recently, another study, using ultrasound, has suggested
frequent occurrence of subclinical synovitis [14]. Apart from
subclinical inflammation, secondary OA in RA may have
caused enhanced joint uptake, as mentioned earlier.
The FM group appeared to be a useful control group with
no FDG uptake in clinically noninflamed joints. The mean
age of FM patients was, however, lower than that of RA and
OA patients. This could actually be an advantage, as
degenerative joints in elderly patients are more likely to
show FDG uptake [3]. The joints of the induced FM patients
did not show any clinical signs of OA.
In conclusion, FDG uptake is primarily seen in active
(subclinical) inflamed RA joints. It may, however, also be
present in degenerative joints and in synovitis secondary to
OA. Distinction between tracer uptake in RA and OA joints
is not possible using FDG-PET. More specific evaluation of
inflamed rheumatoid joints may become feasible by
development of new PET tracers that specifically target
molecular pathways associated with rheumatoid synovitis.
As a potentially very sensitive method of imaging (pico- to
nanomolar concentrations), PET may eventually become a
useful tool in detecting synovitis at an early stage of RA,
allowing early treatment.
Acknowledgements. Dr. GHC Schardijn, rheumatologist, is acknowl-
edged for his contribution in to this study by referring patients with FM and
patients with OA.
Ethics Approval. The study protocol was approved by the medical ethics
committee of the VU University Medical Centre. All patients gave written
informed consent prior to scanning.
References
1. Wandler E, Kramer EL, Sherman O, et al. (2005) Diffuse FDG
shoulder uptake on PET is associated with clinical findings of
osteoarthritis. Am J Roentgenol 185:797Y803
2. Houseni M, Chamroonrat W, Zhuang H, et al. (2006) Facet joint
arthropathy demonstrated on FDG-PET. Clin Nucl Med 31:418Y419
3. Von Schulthess GK, Meier N, Stumpe KD (2001) Joint accumulations
of FDG in whole body PET scans. Nuclearmedizin 40:193Y197
4. Polisson RP, Schoenberg OI, Fischman A, et al. (1995) Use of
magnetic resonance imaging and positron emission tomography in the
assessment of synovial volume and glucose metabolism in patients
with rheumatoid arthritis. Arthritis Rheum 38:819Y825
5. Beckers C, Ribbens C, Andre B, et al. (2004) Assessment of disease
activity in rheumatoid arthritis with [18]F-FDG PET. J Nucl Med
45:956Y964
6. Blockmans D, De Ceuninck L, Van der Schueren S, et al. (2007)
Repetitive 18-fluorodeoxyglucose positron emission tomography in
isolated polymyalgia rheumatica: a prospective study in 35 patients.
Rheumatology 46:672Y677
7. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 31:315Y324
8. Twisk JWR (2006) Applied multilevel analysis. Cambridge: Cam-
bridge University Press, pp Twisk JWR (2006) Applied multilevel
analysis. Cambridge: Cambridge University Press
9. Loesser RF (2006) Molecular mechanisms of cartilage destruction:
mechanics, inflammatory mediators, and aging collide. Arthritis
Rheum 54:1357Y1360
10. D_Agostino MA, Conaghan P, Le Bras M, et al. (2005) Eular report on the
use of ultrasonography in painful knee osteoarthritis part 1: prevalence of
inflammation in osteoarthritis. Ann Rheum Dis 64:1703Y1709
11. Goerres GW, Forster A, Uebelhart D, et al. (2006) F-18 FDG whole
body PET for the assessment of disease activity in patients with
rheumatoid arthritis. Clin Nucl Med 31:386Y390
12. Schmid M, Rodemann HP, Aicher WK (2004) Frequency of terminally
differentiated fibroblasts in the synovial membrane of rheumatoid
arthritis patients. Z Rheumatol 63:483Y489
13. Kraan MC, Versendaal H, Jonker M, et al. (1998) Asymptomatic synovitis
precedes clinically manifest arthritis. Arthritis Rheum 41:1481Y1488
14. Wakefield RJ, Green MJ, Marzo-Ortega H, et al. (2004) Should
oligoarthritis be reclassified? Ultrasound reveals a high prevalence of
subclinical disease. Ann Rheum Dis 63:382Y385
360 E.H. Elzinga, et al.: FDG Joint Uptake on Positron Emission Tomography Images
